RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+21.23%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$631M
AUM Growth
+$631M
(+21%)
Cap. Flow
+$44.8M
Cap. Flow
% of AUM
7.1%
Top 10 Holdings %
Top 10 Hldgs %
26.93%
Holding
113
New
5
Increased
44
Reduced
29
Closed
9
Top Buys
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$15.5M |
| 2 |
Glaukos
GKOS
|
$10.8M |
| 3 |
Esperion Therapeutics
ESPR
|
$9.48M |
| 4 |
Biogen
BIIB
|
$8.75M |
| 5 |
ELGX
Endologix Inc
ELGX
|
$7.42M |
Top Sells
| 1 |
Teva Pharmaceuticals
TEVA
|
$13.1M |
| 2 |
ARIA
Ariad Pharmaceuticals Inc
ARIA
|
$11.1M |
| 3 |
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
|
$5.44M |
| 4 |
Centene
CNC
|
$4.45M |
| 5 |
Bristol-Myers Squibb
BMY
|
$4.35M |
Sector Composition
| 1 | Healthcare | 92% |
| 2 | Financials | 1.18% |
| 3 | Technology | 0.15% |
| 4 | Energy | 0.12% |
| 5 | Consumer Staples | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CMRX
76
DELISTED
Chimerix, Inc.
CMRX
| $2.55M | 0.4% |
400,000
| – | – |
|
77
Coherus Oncology, Inc. Common Stock
CHRS
$146M
| $2.36M | 0.37% |
111,357
| – | – |
|
78
Halozyme
HALO
$8.75B
| $2.2M | 0.35% |
170,000
-10,000
| -6% | -$130K |
|
|
BIVV
79
DELISTED
Bioverativ Inc. Common Stock
BIVV
| $1.69M | 0.27% |
+31,000
| New | +$1.69M |
|
80
Insulet
PODD
$24.2B
| $1.51M | 0.24% |
35,000
| – | – |
|
|
RGLS
81
DELISTED
Regulus Therapeutics
RGLS
| $979K | 0.16% |
593,629
+125,454
| +27% | +$207K |
|
82
Becton Dickinson
BDX
$54.3B
| $917K | 0.15% |
5,000
| – | – |
|
|
TSRO
83
DELISTED
TESARO, Inc.
TSRO
| $769K | 0.12% |
5,000
-15,000
| -75% | -$2.31M |
|
|
ACHN
84
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $699K | 0.11% |
166,000
| – | – |
|
|
CNCE
85
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $513K | 0.08% |
30,099
| – | – |
|
86
Astria Therapeutics
ATXS
$394M
| $497K | 0.08% |
310,756
+210,756
| +211% | +$337K |
|
87
JPMorgan Chase
JPM
$824B
| $425K | 0.07% |
4,837
+750
| +18% | +$65.9K |
|
88
Adverum Biotechnologies
ADVM
$68.2M
| $416K | 0.07% |
154,006
| – | – |
|
|
OREX
89
DELISTED
Orexigen Therapeutics, Inc.
OREX
| $413K | 0.07% |
120,000
| – | – |
|
90
Wells Fargo
WFC
$258B
| $407K | 0.06% |
7,305
+1,187
| +19% | +$66.1K |
|
91
Exxon Mobil
XOM
$477B
| $396K | 0.06% |
4,823
+1,628
| +51% | +$134K |
|
92
Halliburton
HAL
$18.4B
| $380K | 0.06% |
7,718
+2,787
| +57% | +$137K |
|
93
Ocular Therapeutix
OCUL
$2.25B
| $371K | 0.06% |
40,000
| – | – |
|
94
Microsoft
MSFT
$3.76T
| $316K | 0.05% |
4,793
| – | – |
|
95
Qualcomm
QCOM
$170B
| $308K | 0.05% |
5,368
+1,242
| +30% | +$71.3K |
|
96
IBM
IBM
$227B
| $308K | 0.05% |
1,766
| – | – |
|
97
AB InBev
BUD
$116B
| $308K | 0.05% |
2,806
+626
| +29% | +$68.7K |
|
98
Tandem Diabetes Care
TNDM
$834M
| $281K | 0.04% |
234,000
| – | – |
|
99
STAAR Surgical
STAA
$1.35B
| $281K | 0.04% |
28,711
| – | – |
|
100
Ford
F
$46.2B
| $262K | 0.04% |
22,511
| – | – |
|